

09/830761

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PCT
COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231


Sir:

Transmitted herewith for filing is the new patent application of ROLANDO BARBUCCI and ROBERTO RAPUOLI constituting the U.S. National Stage of PCT/EP99/08481 filed November 8, 1999 entitled CROSS-LINKED HYALURONIC ACIDS AND MEDICAL USES THEREOF

Attached are the following documents:

1. English language copy of PCT/EP99/08481 comprising:
 - a. 18 pages of specification
 - b. 2 pages of claims comprising Claims 1-11.
2. Copy of International Search Report
3. Declaration (later)
4. Assignment (later)
5. A Preliminary Amendment
6. A check in the amount of \$860 to cover the filing fee.

Respectfully submitted,



Walter H. Schneider
Attorney for Applicant

19167 Thompson Ridge Rd
Laurelville, Oh. 43135
Tel: 740-332-1049
Fax: 740-332-3023

Atty Dock. 1756

09/830761.061901

BIANCHETTI • BRACCO • MINOJA

STUDIO CONSULENZA BREVETTUALE

09/830,761
04/30/01
#20

Italian Patent Agents
European Patent Attorneys
European Trade Mark Attorneys

Via Rossini, 8
20122 MILANO - Italy
Tel: +39.02.76021218 - 76021192
Fax +39.02.783078 - 76024366
E-mail: mailbox@scb.it

GIUSEPPE BIANCHETTI
Prof. Org. Chemistry

MAURO BRACCO
Public Accountant

MARINA BIANCHETTI
Dr. Medicinal Chemistry

FABRIZIO MINOJA
Dr. Chemistry

PAOLO BANFI
Dr. Medicinal Chemistry



Dr. WALTER H. SCHNEIDER
Attorney at Law
19167 Thompson Ridge Road
LAURELVILLE (Ohio) 43135
United States of America

Milano, May 14, 2001

Your ref. 1756

Our ref. **9009 V/vmf**
(to be indicated in the reply)

DHL

Dear Sirs,

RE.: National phase of PCT/EP99/08481
filed on November 8, 1999
in the name of Aquisitio S.p.A.

With reference to our order letter of April 11, 2001, please find herewith enclosed the Declaration and Assignment duly executed.

The Applicant can be entitled to the "small entity" status.

Yours faithfully,
BIANCHETTI BRACCO MINOJA

Encl.

09830761-061801

7/B

Rec'd PCT/PTO 06 AUG 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Rolando Barbucci)
SERIAL NO. : 09/830,761) Art Unit:
FILING DATE : 04/30/01) Examiner:
TITLE : Cross-Linked Hyaluronic Acids and)
Medical Uses thereof)

BOX PCT
COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

SECOND PRELIMINARY AMENDMENT

Please amend this application as follows:

IN THE CLAIMS:


Please cancel Claim 5.

REMARKS

It was Applicant's intention by the first Preliminary Amendment to cancel all multiple dependent claims. It is submitted that this intent is apparent from the language in the "Remarks" of the Amendment. That the Amendment did not call for cancellation of Claim 5 was entirely through inadvertency on the part of Applicant.

Entry of the Amendment and withdrawal of the requirement for additional claim fee is respectfully requested.

Respectfully submitted



Walter H. Schneider
Attorney of Record

Tel: 74-332-1049
Atty Dock. 1756

09830761-001001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : Rolando Barbucci)
 SERIAL NO. :)
 FILING DATE :)
 TITLE : Cross-Linked Hyaluronic Acids and)
 Medical uses thereof)

BOX PCT
 COMMISSIONER OF PATENTS AND TRADEMARKS
 WASHINGTON, D.C. 20231

SIR:

PRELIMINARY AMENDMENT

Please amend the attached new patent application as follows:

IN THE CLAIMS

Please add the following claims:

---12(New). A cross-linked hyaluronic acid according to
 Claim 3 wherein the hydroxy groups are sulphated or hemisucc-
 inylated.---

---13(New). A cross-linked hyaluronic acid according the
 Claim 3 in gel, semi-solid or solid form.---

---14(New). A metal complex of a cross-linked hyaluronic
 acid according to Claim 3 in which the metal is selected from
 zinc, copper and iron.---

---15(New). Pharmaceutical compositions useful as (a) sub-
 stitutes for synovial fluid in the treatment of osteoarthritic
 conditions and for vitreous humor in the treatment of pathologies

and side-effects connected to ophthalmic surgery; (b) as a base for artificial tears formulation; (c) as controlled release matrices of medicaments; and (d) as healing and anti-adhesive agents; in which the principal ingredient is a cross-linked hyaluronic acid according to Claim 3.---

---16(New). Vascular prosthesis, biohybrid organs, healing devices ophthalmic and otological compositions prothesis, implants and medical devices comprising as a principal ingredient a cross-linked hyaluronic acid in solid or seimi-solid form according to Claim 3.---

Please cancel Claims 6-11.

REMARKS

This Preliminary Amendment is submitted in order to eliminate multiply dependency of claims and to restrict the number of independent claims to three or less.

An Abstract page has been submitted for inclusion as a part of the application.

Entry of the Amendment is respectfully requested.

Respectfully submitted,



Walter H. Schneider
Attorney of Record

Tel: 740-332-1049
Atty Dock. 1756

ABSTRACT

Cross-linked hyaluronic acids produced by the reaction of the carboxylic acid groups of hyaluronic acid and a polyamine and the sulfated and hemisuccinylated derivatives thereof. The cross-linked hyaluronic acids are useful for various pharmaceutical and medical purposes

09330364-061804
FOBT90-7920860

"CROSS-LINKED HYALURONIC ACIDS AND MEDICAL USES THEREOF"

JO 18 REC D PCT/EP 99 0 APR 2001

Field of the invention

5 The present invention concerns cross-linked hyaluronic acids, optionally hemisuccinylated or sulphated, the salts thereof with biologically suitable or pharmacologically active cations and the complexes thereof with heavy metals such as copper, zinc and iron.

10 The invention also concerns the use of said cross-linked hyaluronic acids, salts and complexes in the medical, pharmaceutical and cosmetic fields.

Background of the invention

15 Hyaluronic acid is a glycosaminoglycan consisting of disaccharide units of D-glucuronic acid and N-acetylglucosamino-2-acetamido-2-deoxy-D-glucose, connected by β (1 \rightarrow 3) glycoside bonds.

Natural hyaluronic acid has linear, not cross-linked structure of molecular weight ranging from 50,000 to 8,000,000 D or more, depending on the source and extraction method.

20 Hyaluronic acid is present in the synovial liquid, connective tissue and vitreous humor of higher animals, as well as in some bacteria.

25 Compositions of sodium hyaluronate having various molecular weights (in the form of solutions having different viscosities, gels with different viscoelastic characteristics, sponges, films or membranes) are used in human medicine and surgery for instance as substitutes of synovial liquid, tissular antiadhesive agents, substitutes of vitreous humor, artificial tears, agents for the in vivo tissular re-constitution (for instance as extra-cellular matrices for the formation of bone segments, following the colonisation of osteoblasts and subsequent calcification; of connective-dermal tissues, following the

colonisation of fibroblasts), materials for the preparation of artificial skin useful in the treatment of burns or in plastic surgery; coating agents for biocompatible vascular prosthesis, carriers of pharmacologically active ingredients in controlled-release formulations, etc.

5 In dermatology and cosmetology, in view of the viscoelastic and moisturising properties and of the high biocompatibility, said compositions are used both as bases for moisturising topical formulations and as invasive medical-surgical devices ("filling agents").

10 The use of natural, linear hyaluronic acid for said uses is however limited by its in vivo fast degradation by enzymatic systems such as hyaluronidase, glucosidase and glucuronidase, with subsequent decrease in the molecular weight and progressive impairment of the viscoelastic properties and, generally, of the physical characteristics of the final compositions and devices (mechanical strength, elasticity, pore size,) etc.

15 In order to overcome this problem, mainly with the purpose of increasing the range of compositions and their applicative flexibility, chemically modified hyaluronic acids have been proposed.

20 Cross-linking with polyfunctional epoxides (US 4716224, 4772419, 4716154), polyalcohols (US 4957744), divinylsulphone (US 4582865, 4605601, 4636524), aldehydes (US 4713448, 5128326, 4582568), biscarbodiimides (US 5356883), polycarboxylic acids (EP - A- 718312) has been disclosed.

25 Said cross-linked hyaluronic acids are used as biomaterials for implants, prosthesis and medical devices, as controlled-release matrices for medicaments, as healing, anti-adhesive and dressing agents.

The sulphation of non cross-linked hyaluronic acid is generally disclosed in US 5013724, mainly concerning the sulphation of heparines, heparans and dermatans for use as antithrombotic and anti-coagulant agents.

The hemisuccinylation recreation of hyaluronic acid (HY) has never been disclosed. An example of this functionalization is disclosed in EP - B-200574, claiming composite biomaterials consisting of succinylated collagen and chitosan.

5 The cross-linking of carboxyalkyl cellulose by means of di - or polyamines is disclosed in EP-A-566118 (Kimberly Clark Corp) for the preparation of absorbing materials with HY as cross-linking agent, by heating. Such a method appears to be economically advantageous and suitable for the large-scale productions required for this kind of products.

10 EP-A-462 426 (Fidia) discloses perforated biocompatible membranes and their uses as artificial skin. Collagen cross-linked with diamines and hyaluronic acid are generically cited as possible materials for said membranes.

Summary of the invention

15 It has now been found that new cross-linked hyaluronic acids obtainable by reaction of suitably activated carboxy groups of HY with a polyamine, as well as the salts and complexes with suitable organic or inorganic cations, have advantageous chemico-physical and biological properties for the biomedical and cosmetic uses.

20 The main chemico-physical and biochemical characteristics of the compounds of the invention are:

- high biocompatibility;
- high resistance to enzymatic degradation mainly after sulphation;
- high capacity to adsorb water, with formation of visco-elastic characteristics dependent on the cross-linking degree as well as on sulphation and/or hemi-succinylation degree;
- ability to chelate metal ions such as zinc or copper; said derivatives having very good stability.

09830761-061801

The biological behaviour is new and surprising; it is known that sulphation (or supersulphation) of glycosaminoglycans such as heparin, dermatan sulphate, chondroitin and native hyaluronic acid is known to increase their anti-coagulant properties (inhibition of Xa and IIa factors and/or change of their ratio) with respect to the starting product (US 5013724).

The compounds of the invention, when sulphated, have a slight anticoagulant activity, whereas it is completely surprising the lack of platelet activation and aggregation (measured as antiadhesive activity; P.R.P. model in rabbits subjected to behavioural stress, described in "Abstract IL 15" -- International Conference on Advances in Biomaterials and Tissue Engineering, 14-19 Juin 1998, Capri Italy) both for the cross-linked hyaluronic acid of the invention (with different cross-linking degrees) and for the corresponding sulphate esters; this property is totally absent in the natural hyaluronic acid and esther derivatives.

No polymeric materials for medical use up to now known apparently shares the same property.

Detailed disclosure of the invention

The invention concerns new cross-linked hyaluronic acids obtainable by reaction of activated carboxylic groups of native linear hyaluronic acid, of extractive or biosynthetic route, with a polyamine, particularly a linear alkyl diamine.

According to a preferred embodiment, the cross-linked hyaluronic acid of the invention is further subjected to sulphation and hemisuccinylation processes. The obtained products and their salts or complexes have entirely new properties (for instance, swelling, water motility within the gel; chemotactic activity on endothelial cells, viscoelastic properties).

Said esterification processes are carried out by known methods (use of

reagents pyridine/SO₃; chlorosulphonic acid; succinic anhydride, in homogeneous or heterogeneous phase, at pH from 6.5 to 8).

Examples of the hemisuccinylation process for collagen are reported in WO 88/10123 and in US 4493829.

5 The polyamine to be used as cross-linking agent according to the invention is preferably a diamine of formula R₁NH-A-NHR₂ wherein A is a C₂ - C₁₀ linear or branched alkylene chain, preferably a C₂ - C₆ chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy and amino groups; a polyoxyalkylene chain [(CH₂)_n-O-(CH₂)_n]_m wherein n is 2 or 3, m is an integer from 2 to 10; a C₅-C₇ cycloalkyl group; an aryl or hetaryl group, preferably 1, 4 or 1,3 disubstituted benzene; R₁ and R₂, which are the same or different, are hydrogen, C₁-C₆ alkyl, phenyl or benzyl groups.

Preferred meanings of A are C₂ - C₆ alkylene or a chain [(CH₂)_n-O-(CH₂)_n]_m. R₁ and R₂ are preferably hydrogen.

15 The polyamine is reacted with hyaluronic acid or salts thereof, the carboxylic groups of which have been previously activated.

The activation may be carried out with conventional methods; for instance, and preferably, those commonly used, in anhydrous aprotic solvent, to form amide bonds in peptide synthesis such as carbonyldiimidazole; carbonyl-triazole; hydroxybenzotriazole; N-hydroxysuccinimide; p-nitrophenol + p-nitrophenyltrifluoro acetate, chloromethylpyridylium iodide; preferably chloromethylpyridylium iodide and like; these activators allow the best yields and the highest reproducibility in terms of cross-linking degree.

25 The hyaluronic acid is preferably salified with a lipophilic cation, for instance tetralkylammonium or other lipophilic organic bases able to induce the suitable solubility in the polar aprotic solvent such as dimethylformamide, tetrahydrofuran or the like.

The transformation of inorganic salts such as sodium into suitable organic cations may be carried out by well known ion-exchange methods in homogeneous phase or by precipitation of the acid component, its recovery and subsequent salification with the desired organic base.

5 The activation reaction of the carboxy groups is usually carried out in homogeneous phase and in anhydrous polar aprotic solvent.

10 The cross-linking polyamine is added to the solution of the activated ester in the same anhydrous solvent, keeping the temperature from 0 to 30°C. The reaction times range from 1 to 12 hours, depending on the presence of suitable bases such as triethylamine.

In general, the desired final product is recovered by addition of a different solvent under reduced pressure, followed by conventional work-up.

15 The cross-linking degree may be comprised within wide limits and may be adjusted by changing the amount of the carboxy-activating agent, the activation and the cross-linking reactions being practically quantitative.

As a consequence, the desired cross-linking degree (C.L.D.: percent of carboxylic groups involved in the cross-linking) is perfectly reproducible, as shown by the N.M.R. data. The final products obtained under similar operative conditions have therefore constant characteristics.

20 The starting hyaluronic acid may be any hyaluronic acid having molecular weight from about 5.000 to 8,000,000 D, preferably from 10.000 to 200,000 D, extracted from conventional sources or obtainable by fermentation of microorganisms of the group Streptococcus or other engineered strains.

25 The cross-linked hyaluronic acid of the invention may be subjected to sulphation reaction with a suitable reagent, preferably the pyridine/sulphur trioxide complex in dimethylformamide.

The reaction is carried out in heterogeneous phase at a temperature of

09830761.061801

0-10°C for reaction times ranging from about 0,5 to about 6 hours.

The obtainable sulphation degree may be comprised within wide limits and may be adjusted by changing the reaction time and the temperature.

Generally, the sulphation degree (defined as eq. Sulphate groups/g) may range from 1×10^{-6} to 6×10^{-6} , preferably about 2×10^{-6} eq./g for a C.L.D. = 0.5.

The cross-linked hyaluronic acid of the invention may also be subjected to hemisuccinylation reactions in known conditions (aqueous heterogeneous phase, under strong stirring, addition of solid succinic anhydride in subsequent portions, in ratios from 1:1 to 1:5 by weight; keeping the pH from 7 to 8.5 with alkali, at temperatures ranging from 5 to 30°C). The hemisuccinylation degree may be comprised within wide limits depending on the following parameters: reaction time and temperature; stirring speed of the polyphasic system and addition rate of solid succinic anhydride. By keeping said parameters constant, the reaction gives reproducible products. The cross-linked hyaluronic acids, optionally sulphated or hemisuccinylated, of the invention show the ability to form complexes with metal ions such as copper, zinc, iron.

These complexes may be easily obtained by dissolving or by dispersing until complete swelling the hyaluronic acid derivative in water and adding under stirring preferably at room temperature, a concentrated solution of an organic or inorganic salt of copper, zinc or iron, for instance CuCl_2 , ZnCl_2 , or $\text{Fe}_2(\text{SO}_4)_3$; after 12-24 hours under stirring, the complex is recovered by centrifugation or precipitation following change of solvent (e.g. addition of ethanol or acetone) or evaporation under reduced pressure; the recovered crude product is thoroughly washed with distilled water so as to remove the excess ion.

The complexes are then freeze-dried.

The content of metal ions depends on the used operative conditions: polymer to ion molar ratios, concentration and pH of the solution; reaction times and particularly the cross-linking degree. It may reach the maximum volume of 1 metal ion per disaccharide unit not involved in the cross-linking.

An important advantage of the invention consists in the possibility of obtaining, by suitably changing the cross-linking degree and/or the sulphation or succinylation degree, hyaluronic acid derivatives in a wide range of different forms, characterised by different properties (such as visco-elasticity, metal ions, ability to form hydrogels, films, sponges, mechanical strength etc.).

This allows the use of the hyaluronic acid derivatives of the invention in several medical and pharmaceutical fields, in the human or veterinary field:

- 1) as intraarticular substitutes of the synovial liquid for the treatment of osteoarthritic conditions;
- 2) as vitreous humor substitutes for the treatment of pathologies and side-effects connected to ophthalmic surgery;
- 3) as base of artificial tears formulation, suited for the therapy of dry eye;
- 4) as controlled - release matrices of medicaments (e.g. antiinflammatories, antibiotics, β -adrenergic agonists and antagonists, aldose reductase inhibitors, anti-acne, antiallergic, anti-alopecia, antineoplastic, antiglaucoma, anti-itching, anti-psoriasis, anti-seborrhea, anti-ulcer, antiviral agents, growth factors etc.) by simple inclusion into the hydrogels obtained from the compounds of the invention. Alternatively to the inclusion process, the medicament may be bound by covalent bonds to the

hyaluronic acid matrices, by means of:

- a) esterification or amidation of COOH not involved in the cross-linking with polyamines, when the medicament is an alcohol or an amine;
- b) esterification with the free hydroxy groups of hyaluronic acid derivatives when the medicament has free carboxy groups.

The products under a) may be obtained using the same activation method of the carboxy groups described above in a carefully anhydrous medium or by transesterification.

5) For the preparation of device for wound or skin ulcers healing in form of films of different thickness, more or less permeable to gases, sponges etc. Said devices preferably contain suitable drugs such as antibiotics, healing factors. They are also useful in the culture of epithelial cells, keratinocytes etc.;

6) For all the applications for which the use of known hyaluronic acids has already been proposed, for instance the preparation of solid or semi-solid forms or moldable form for the production of vascular prosthesis (antiadhesive dressings of blood vessels, artificial heart valves etc.); of biohybrid organs (artificial pancreas, liver); of ophthalmic products (lens substitutes, contact lens); of otological products; generally of anti-adhesive implants, to be used in abdominal, gynaecological, plastic, orthopaedic, neurological, ophthalmological, thoracic, otorhinolaryngological surgery; of medical device such as stents, catheters, cannulas and the like.

The uses of cross-linked hyaluronic acid and of biomaterials obtained therefrom are known and described, for instance, in WO 97/39788, WO 97/22629, WO 97/18244, WO 97/7833, EP 763754, EP 718312, WO 96/40005, WO 96/33751, US 5532221, WO 95/1165 e EP 320164.

The use of the cross-linked hyaluronic acids of the invention in cosmetic dermatology is of particular interest, for instance as moisturizing agents, bases of various cosmetological formulations, injectable filling agents etc.

5 The formal products obtained from the cross-linked hyaluronic acid derivatives of the invention may be subjected to sterilisation processes (for instance by heating to 120°C or by means of ethylene oxide) without any change in the technological properties, which is of course a further advantage provided by the present invention.

10 The present invention is described in more detail in the following examples.

EXAMPLE 1

15 Hyaluronic acid sodium salt (1×10^{-3} mol., with reference to the disaccharidic unit) were transformed in TBA salt, according to one of the following methods:

a) 1% aqueous solution of sodium hyaluronate is transformed in H^+ form by H^+ cationic strong resin (Amberlite IR 120); the final solution is treated by a 0,5% solution of TBA-OH to about pH=9.

20 b) 1% aqueous solution of sodium hyaluronate is transformed in TBA salt solution by treating with a cationic weak resin in TBA^+ form. (Amberlite IRC 50)

25 In both cases, the final solutions are lyophilised. The TBA salt is then dissolved in 15 ml of anhydrous DMF, under N_2 , and – at 0°C – 0,02 g of chloromethylpyridinium Iodide (CMPJ) in 2 ml of anhydrous DMF, are added dropwise to the stored solution of TBA.salt.

The reaction mixture was then added with 0.1 ml of triethylamine and, then, dropwise, with a solution of 1,3-diaminopropane ($d = 0.88$, in large excess, so as to make cross-linking of the activated carboxy groups easier)

in 2 ml of anhydrous DMF. When the addition was over, the reaction mixture was stirred for at least 30' and the solvent was then removed under reduced pressure, the residue was then taken up with DMF, which was subsequently removed by distillation; the residue was then treated with ethanol, ethanol-water and finally with water.

The product was then lyophilised and the residue subjected to analysis.

I.R. (film): 1630 cm^{-1} ($-\underline{\text{CO}}-\text{NH}$); 1740 cm^{-1} ($-\underline{\text{COOH}}$, polysaccharide); 3200 cm^{-1} ($-\text{NH}-$).

SD (Swelling Degree, in water and r.t., after 15'; gravimetric determination; calculated according to: $\text{SD} = \frac{W_s - W_d}{W_d} \cdot 100$, where :

W_s = weight of hydrated gel; W_d = weight of dry gel): 31.000

Cross-linking degree: 0.05 (5% of initially available carboxy groups).

EXAMPLE 2

According to the procedure and conditions reported in example 1, using the same HY and the same activating agent but 1,6-diaminohexane instead of 1,3-diaminopropane, a cross-linked hyaluronic acid having cross-linking degree of 0.05 was obtained.

I.R. (film): 1630 cm^{-1} ($-\underline{\text{CO}}-\text{NH}$); 1740 cm^{-1} ($-\underline{\text{COOH}}$ polysaccharide); 3200 cm^{-1} ($-\text{NH}-$).

EXAMPLE 3

According to the procedure and conditions used in example 1, using as a cross-linking agent 0,0'-dis-(2-aminopropyl) PEG 500, a hyaluronic acid having a cross-linking degree of 0.05 was obtained.

I.R. (film): 1630 cm^{-1} ($-\underline{\text{CO}}-\text{NH}$); 1740 cm^{-1} ($-\underline{\text{COOH}}$ polysaccharide); 3200 cm^{-1} ($-\text{NH}-$).

SD = 31.000

EXAMPLE 4

0.6 g of hyaluronic acid tributylammonium salt (1×10^{-3} mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.08 g of chloromethylpyridylum iodide (3.5×10^{-4} mol) dissolved in 2 ml of DMF were added dropwise to the stirred solution kept at 0°C. The molar ratio was therefore about 3/1.

After 20 minutes 2 ml of 1,3-diaminopropane (0.024 mol) were added, followed immediately by 0.5 ml of triethylamine. A solid, gelatinous product was obtained, the product was then swelled with water and washed again with ethanol.

The final product, after lyophilisation, shows at the scanning microscope an irregular pattern with smooth zones alternating to spongy zones.

The cross-linking degree was 0.3 (30% of initially available carboxy groups)

I.R. (film): 1740 cm^{-1} ($-\text{COOH}$); 1630 cm^{-1} ($-\text{CO-NH}$); 1610 cm^{-1} ($-\text{COO}-$); 1560 cm^{-1} ($-\text{CO-NH-}$)

EXAMPLE 5

0.6 g of hyaluronic acid tributylammonium salt (HY TBA) (1×10^{-3} mol., with reference to the disaccharide unit) were dissolved under stirring in 30 ml of DMF under nitrogen. 0.15 g of chloromethylpyridylum iodide (CMPJ) (6×10^{-6} mol) dissolved in 2 ml of DMF were added dropwise to the solution, kept at 0°C. The molar ratio was 2HY.TBA:1 CMPJ. After 20 minutes, 2 ml of 1,3 diaminopropane (0.024 mol.) were added to the solution.

0.5 ml of triethylamine were added thereafter.

A solid, gelly-like product was obtained and thoroughly washed with DMF.

After evaporating DMF, the product was swelled in water and washed with ethanol before lyophilization.

The obtained product had a cross-linking degree of 0.5 and showed at the scanning microscope a grainy aspect interspaced by large meshes. At higher magnitudes, the two morphologies appear identical and show round-shaped protrusions a few microns in diameter.

IR (film): 1740 cm^{-1} ($-\underline{\text{COOH}}$); 1630 cm^{-1} ($-\underline{\text{CO}}-\text{NH}-$); 1610 cm^{-1} ($-\underline{\text{COO}}-$); 1560 cm^{-1} ($-\text{CO}-\underline{\text{NH}}-$);

The gels were subjected to swelling in PBS and the max swelling ability was evaluated.

SD= 23.500

NMR = (13 C; ppm): 29.3 and 39.8 ($-\overset{1}{\text{CH}_2}-\overset{2}{\text{CH}_2}-\overset{3}{\text{CH}_2}-$ propanediamine link); 172.5 ($-\overset{\cdot}{\text{C}}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{O} \end{array}$$

The rheological properties evaluated on Bohlin VOR Rheometer, at the temperature of $23 \pm 0.1^\circ\text{C}$, show that the dynamic elastic module G' (100Pa at 10Hz) identical at the two considered concentrations (10 and 20 mg/ml) is always higher than the viscous dynamic module (G'' 40 Pa for 20 mg at 10Hz and 20 Pa for 10 mg at 10Hz).

EXAMPLES 6 - 9

According to the methods disclosed in the previous examples, the cross-linked hyaluronic acid derivatives having the characteristics summarised in the following table 1, were obtained, starting from 1×10^{-3} mol (0.6 g) of hyaluronic acid tributylammonium salt.

The obtained derivatives had the following properties

TABLE 1

Ex	Cross-linking agent (mol)	Amount (g) of CMPJ (mol)	Cross-linking degree	SD	NMR (13) (ppm)	I.R. (film) (cm ⁻¹)	Aspect at the scanning microscope
6	1,3-propanediamine (0.024)	0,6g (1.210 ⁻³)	(100%)	13.200	29.3/39.8 (-CH ₂ -CH ₂ -CH ₂ -propanediamine link); 172.5 (-C(=O)-NH-CH ₂ -CH ₂ -CH ₂ -)	1630 (-CO-NH-); 1560 (-CO-NH-);	Homogeneous, undulated morphology.
7	0,0'-1-bis-(-2-diaminopropyl) PEG 500 (0.022)	0,15g (6x10 ⁻⁴)	(50%)	9.000			Alternating smooth areas and meshes, circular protrusions a few microns in size.
8	0,0'-bis (2-aminopropyl) - PEG 800 (0.022)	0,15g (6x10 ⁻⁴)	(50%)	6.100			Two morphologically different zones, a first one undulated and a second with hole-like structures.
9	1,6-diaminohexane (0.023)	0,15g (6x10 ⁻⁴)	(50%)	8.000	169.46(-CO-NH- of cross-linking); 74.04/76.80/83.17/80.41(-CH ₂ - of cross-linking arm)	1740 (-COOH); 1630 (-CO-NH-); 1610 (-COO-); 1560 (-CO-NH-);	Smooth surface with protrusions having a few microns in size.

EXAMPLE 10: Sulphation of 50% cross-linked HY,

The derivative obtained in example 5 was dispersed in 5 ml DMF under strong stirring and nitrogen atmosphere.

A solution of 1 g of SO_3 /pyridine in mol of DMF was added at 0°C and stirred for 3 hours. The reaction was blocked by adding an excess of H_2O (50 ml) and the pH adjusted to 9 with 0.1M NaOH.

The product was thoroughly washed with ethanol and H_2O and then lyophilized.

The IR spectrum shows, in addition to the bands of the starting product, a peak at 1260 cm^{-1} and a stronger band at 1025 cm^{-1} .

The gel swells in PBS with $\text{SD} = 33.000$. Higher resolution ^{13}C NMR spectrum shows the signals in H_2O at 37°C reported in table 2. The intensity of the NMR signals at 29.3 and 38.8 ppm ($-\text{CH}_2-$) and the signal at 172.5 ppm (CONH) confirm a cross-linking degree of about 50%.

The rheological properties are characterised by dynamic elastic modules G' (2500Pa with 20 mg and 1000 Pa with 10 mg at 10Hz) which are always higher than the dynamic viscous modules G'' (600Pa with 20 mg and 150 Pa with 10 mg at 10Hz) and much higher than the corresponding values obtained with non-sulphated HY (13 at 50% - example 5). This compound has a thrombin time (TT) higher ($61 \pm 5''$) than the control (14.0'') and the corresponding not cross-linked (14.6'').

The compound was also active in the PRP test using stressed rabbit.

TABLE 2

Table: ¹³C Chemical shift

C-1	C-2	C-3	C-4	C-5	x-C=O	y-CH ₃	
103.5	57.3	85.4	71.3	78.7	178.0	25.3	ppm
C-1'	C-2'	C-3'	C-4'	C-5'	6-C=O		
105.9	75.2	76.4	82.8	78.6	176.2		ppm
1-CH ₂	2-CH ₂	3-CH ₂	6'-C=O	CROSS- LINKING			
39.8	29.3	39.8	172.5				ppm

5 **EXAMPLE 11:** Using the same methodology, the sulphated derivatives of 50% cross-linked products according to example 7,8, and 9, have been synthesized.

Colorimetric characteristics of the sulphated derivatives are reported in table 3 together with that of the products deriving from examples 5 and 10.

10

15

20

T03T90-T9Z0E860

TABLE 3

CROSSLINKED (50% DEGREE)	POLYMER CROSS.LINKING	ΔH_a [J/g]	T_g [°C]	ΔH_b [J/g]	Wt % water
C.L.Hyal - 1,3 (Ex. 5)		276	51	42	12
C.L.HyalS - 1,3 (Ex. 10)		357	64	53	16
C.L.Hyal - 1,6 (Ex. 9)		327	64	58	16
C.L.HyalS - 1,6		465	64	65	20
5 C.L.Hyal - P500.2NH ₂ (Ex. 7)		239	45	72	10
6 C.L.HyalS - P500.2NH ₂		384	69	113	16
7 C.L.Hyal - P800.2NH ₂ (Ex. 8)		179	73	30	10
8 C.L.HyalS - P800.2NH ₂		206	76	52	10
Hyal ITBA		164	-	130	5

 ΔH_a [J/g]: water vaporization henthalpy T_g [°C]: enthalpy for thermal degradation process ΔH_b [J/g]: glass transition temperateWt % water: % of water content, based on ΔH_a

10 The analysis (EDAX, polarography, HCl 0.1 N titration, atomic
adsorption) shows a copper content of 0.5 mol/disaccharide units.

EXAMPLE 12: Preparation of complexes of Cu, Zn and Fe.

100 mg of lyophilized gel of the example 5 were added, under stirring and at room temperature, to 200 ml of a concentrated solution of copper (II) chloride in distilled water. The suspension was stirred for 24 hours, and the complex was precipitated by addition of ethanol. After centrifugation, the residue was washed repeatedly with water and ethanol to remove the excess ions.

The final gel, blue-green in color, was lyophilized and analyzed.

The same procedure was carried out using ZnCl_2 and FeCl_2 .

The analysis (EDAX, polarography, HCl 0.1 N titration, atomic adsorption) shows a copper content of 0.5 mol/disaccharide units.


09630761.061801

CLAIMS

1. Cross-linked hyaluronic acids obtainable by reaction of the carboxylic groups of hyaluronic acid and a polyamine.


2. Cross-linked hyaluronic acids according to claim 1 wherein the polyamine is a diamine.

3. Cross-linked hyaluronic acids according to claim 2 wherein the diamine has the formula



wherein A is a C₂ - C₁₀ linear or branched alkylene chain, preferably a C₂ - C₆ chain, optionally substituted by hydroxy, carboxy, halogen, alkoxy and amino groups; a polyoxyalkylene chain [(CH₂)_n-O-(CH₂)_n]_m wherein n is 2 or 3, m is an integer from 2 to 10; an aryl or hetaryl group, preferably 1, 4 or 1,3 disubstituted benzene; R₁ and R₂, which are the same or different, are hydrogen, C₁-C₆ alkyl, phenyl or benzyl groups.

4. Cross-linked hyaluronic acids according to claim 3 wherein A is a linear C₂ - C₆ alkylene or a chain of formula



wherein n is 2 and m is an integer from 2 to 10.

5. Cross-linked hyaluronic acids according to any one of claims 1 to 4 wherein the hydroxy groups are sulphated or hemisuccinylated.

6. Cross-linked hyaluronic acids according to any one of the previous claims in the form of gel.

7. Cross-linked hyaluronic acids according to any one of the previous claims in solid or semi-solid forms.

8. Complexes of zinc, copper or iron of claims 1-7.

9. The use of cross-linked hyaluronic acids derivatives of claims 6 and 8 as substitutes of synovial fluid, vitreous humor, as controlled-release matrices forms medicaments, as healing and antiadhesive agents.

10. The use of cross-linked hyaluronic acids derivatives of claim 7 for the preparation of vascular prosthesis, biohybrid organs, healing devices, ophthalmic and otological compositions, prosthesis, implants and medical devices.

- 5 11. Biomaterials comprising the cross-linked hyaluronic acids of claims 1 - 8.

09830751.061801

DECLARATION AND POWER OF ATTORNEY

U.S.A.

As a below-named inventor, I hereby declare: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Cross-linked hyaluronic acids and medical uses thereof, the specification of which

(check) ☐ is attached hereto.
(one)

☒ was filed on April 30, 2001 as Application Serial No. 09/830,761

and was amended on April 30, 2001 (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above, and acknowledge a duty to disclose information which is material to the examination of this application under 37 CFR 1.56(a). I hereby claim priority benefits under 35 U.S.C. 119 based on any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate on the present invention, filed before the application(s) on which priority is claimed.

FOREIGN APPLICATION(S), IF ANY, REFERRED TO ABOVE			
COUNTRY	APPLICATION NUMBER	DATE	PRIORITY CLAIMED
Italy	MI98A002440	11.11.1998	YES <u>X</u> NO <u> </u>
			YES <u> </u> NO <u> </u>
			YES <u> </u> NO <u> </u>

I hereby claim benefit under 35 U.S.C. 120 of any U.S. application(s) listed below. If the subject matter of any claim(s) of this application is not disclosed in the prior U.S. application(s) as required by paragraph one of 35 U.S.C. 112, I acknowledge a duty to disclose material information as defined in 37 CFR 1.56(a) regarding occurrences between the filing date of the prior application(s) and the national or PCT international filing date of this application:

APPLICATION SERIAL NUMBER	DATE	STATUS

I hereby appoint Walter H. Schneider
Reg. No. 16812

Burton A. Amernick
Reg. No. 24852

my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

Address all communications to Walter H. Schneider
5715 Strathmore Lane, Dublin, Oh. 43017

All statements made herein of my own knowledge are true. All statements made on information and belief are believed to be true. These statements were made with the knowledge that willful false statements and the like so made are punishable by fine, imprisonment, or both, under 18 U.S.C. 1001 and may jeopardize the validity of the application or any patent issuing thereon.

Note: Please sign one full given name and your surname, using initials where appropriate for other names. It is important that the name be consistent throughout the application papers. Signing of an application more than five weeks prior to filing or an undated application is not acceptable to the Patent and Trademark Office except for receiving an initial filing date.

Full name of inventor BARBUCCI Rolando Date: 02.05.2001

Inventor's signature [Signature]

Residence Piazzale Aquileia, 8 - Milano, Italy ITX

Citizenship Italian

Post Office Address same as above

Full name of inventor RAPPUOLI Roberto Date: 02.05.2001

Inventor's signature [Signature]

Residence Piazzale Aquileia, 8 - Milano, Italy ITX

Citizenship Italian

Post Office Address same as above